home / stock / pasg / pasg news

PASG News and Press, Passage Bio Inc. From 11/05/25

Stock Information
Company Name: Passage Bio Inc.
Stock Symbol: PASG
Market: NASDAQ
Website: passagebio.com
Menu
PASG PASG Quote PASG Short PASG News PASG Articles PASG Message Board
Get PASG Alerts

News, Short Squeeze, Breakout and More Instantly...
PASG - Passage Bio to Present at Guggenheim Securities 2nd Annual Healthcare Innovation Conference

PHILADELPHIA, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M.D., president and chief executive officer, will participate in...
PASG - Passage Bio to Participate in Chardan's 9th Annual Genetic Medicines Conference

PHILADELPHIA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M.D., president and chief executive officer, will participate in...

PASG - Passage Bio to Participate in H.C. Wainwright 27th Annual Global Investment Conference

PHILADELPHIA, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that management will participate in the H.C. Wainwright 27th Annual Global Inves...

PASG - Expected earnings - Passage Bio Inc.

Passage Bio Inc. (PASG) is expected to report $-4 for Q2 2025
PASG - Passage Bio GAAP EPS of -$2.96 beats by $1.08

2025-08-12 07:39:18 ET More on Passage Bio Seeking Alpha’s Quant Rating on Passage Bio Historical earnings data for Passage Bio Financial information for Passage Bio Read the full article on Seeking Alpha For further details see: Passage Bi...

PASG - Passage Bio Reports Second Quarter 2025 Financial Results and Provides Recent Business Highlights

Completed dosing of FTD-GRN Cohort 2 in upliFT-D study Reported updated interim data showing that PBFT02 continued to demonstrate robust, durable elevation in CSF PGRN levels and improvement in plasma NfL, a disease progression biomarker, compared to natural history Submit...

PASG - Passage Bio to implement 1-for-20 reverse stock split

2025-07-10 08:05:56 ET More on Passage Bio Seeking Alpha’s Quant Rating on Passage Bio Historical earnings data for Passage Bio Financial information for Passage Bio Read the full article on Seeking Alpha For further details see: Passage Bi...
PASG - Passage Bio Announces 1-for-20 Reverse Stock Split

PHILADELPHIA, July 10, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (“ Passage Bio ” or the “ Company ”) (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that it...

PASG - Passage Bio Reports Updated Interim Data from upliFT-D Study and Provides Program Update

PBFT02 continued to demonstrate robust, durable elevation in CSF PGRN levels and improvement in plasma NfL, a disease progression biomarker, compared to natural history Dose 2, 50% lower than Dose 1, substantially increased CSF PGRN levels at 30-days, reaching the upper limit of a healthy...

PASG - Passage Bio GAAP EPS of -$0.25 misses by $0.02

2025-05-13 07:53:27 ET More on Passage Bio Passage Bio GAAP EPS of -$1.07 misses by $0.12 Seeking Alpha’s Quant Rating on Passage Bio Historical earnings data for Passage Bio Financial information for Passage Bio Read the full article on Seek...
Previous 10 Next 10